Insights

How did ASX healthcare shares perform in the FY22 first quarter?

ASX healthcare shares have pivoted from the major benchmarks in Q1 to book gains.
The post How did ASX healthcare shares perform in the FY22 first quarter? appeared first on The Motley Fool Australia. –

As we make our way through the first half of FY22, equity markets have begun to shake up somewhat in the last few weeks.

The benchmark S&P/ASX 200 Index (ASX: XJO) has slumped almost 4.5% into the red over the last month, back to its May 2021 levels.

Leading the way is the S&P/ASX 200 Health Care Index (XHJ), which has slipped around 6% lower in the last month.

Let’s zoom out and look at how ASX healthcare shares have performed in Q1 FY22.

How did ASX healthcare shares go in Q1 FY22?

As a whole, ASX healthcare shares were in the green for the first quarter, in a robust performance on the local exchanges.

The ASX 200 Health Care index has climbed 1.3% this past quarter, and now leads the benchmark index over this time.

Broad weakness across the ASX has stemmed a 3-month decline for the major indices, with the S&P/ASX 200 handing back just over 1% in Q1.

So as it stands, taking a broad view, ASX healthcare shares outperformed the market in the first quarter of FY22.

Impressive gains are observed on the individual share level for Q1 in this sub-group.

For instance immunotherapy company Imugene Limited‘s (ASX: IMU) share price has climbed from 35 cents to 47.5 cents in the last quarter, a 36% jump.

Not to mention, the Imugene share price came off lows of 28 cents on 9 August to reach its all-time high in Q1 FY22.

Medicinal cannabis company Incannex Healthcare Ltd (ASX: IHL) was also a winner, with shareholders clipping the ticket on a 35% bump in its share price last quarter.

Ramsay Health Care Limited (ASX: RHC) shares were also climbers in Q1, delivering an outsized return of 11% after a healthy $6.80 per share gain from July to 30 September.

However, it wasn’t all rainbows for the sector, with some names coming in well behind the benchmarks.

After some excitement earlier in the year, the Little Green Pharma Ltd (ASX: LGP) share price made a 26% march down south from highs of 93 cents.

In and around the small to large cap names, there are instances of both underperformance and outsized returns.

Foolish takeaway

In the last month, the ASX healthcare indices have led the market’s losses. Within this group, some shares are outperforming while others are lagging behind their key benchmarks.

Nonetheless, as a whole, ASX healthcare shares appear to have outperformed the broad index in the last quarter.

The post How did ASX healthcare shares perform in the FY22 first quarter? appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

More reading

Top brokers name 3 ASX shares to sell next week

Ramsay (ASX:RHC) share price on watch on Friday after update
The Incannex (ASX:IHL) share price has lost 20% in 4 weeks. What’s happening?
5 things to watch on the ASX 200 on Thursday

Little Green Pharma (ASX:LGP) share price lifts as bosses reflect on a big year

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!